Thu.May 02, 2024

article thumbnail

Scientists spot an orangutan using a plant to treat his own wound in the wild

STAT

When male Sumatran orangutans let out a long call, they’re usually trying to grab female attention. But the sounds — a booming blend of roars and grunts — can end up attracting unwanted attention from other males, too. Things can get tense. Which is likely how Rakus, an adult male orangutan frequently seen in Gunung Leuser National Park in South Aceh, Indonesia, acquired a face wound in June 2022.

364
364
article thumbnail

$4M+ gene therapies? How payers can adapt to a new reality of pricey ‘cures’

PharmaVoice

Pricey gene therapies promise great benefit to patients but pose a threat to the payer landscape — ICER and a Tufts think tank are offering potential solutions.

245
245
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bird flu virus circulated in cows for four months before outbreak confirmed by USDA, analysis shows

STAT

As agricultural authorities and epidemiologists try to get their arms around the scope of the latest confounding chapter in the decades-long story of the H5N1 avian influenza virus — its j ump into U.S. herds of dairy cattle — they’re turning to the genetic breadcrumbs the virus leaves behind in the animals’ nose, lungs, and, primarily, milk.

363
363
article thumbnail

Long-acting antibody demonstrates promising efficacy in infant RSV

European Pharmaceutical Review

Interim results of an ongoing study published in The Lancet have reported that Beyfortus (nirsevimab) reduced respiratory syncytial virus (RSV) hospitalisations by 82 percent in infants under six months, compared to infants who received no RSV intervention. Sanofi noted that as a long-acting antibody, Beyfortus has been shown to provide rapid protection, helping to prevent lower respiratory tract disease caused by RSV without the immune system needing activation.

Hospitals 122
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Tracking bird flu virus changes in cows is stymied by missing data, scientists say

STAT

Another upload of genetic sequence data from the H5N1 bird flu outbreak in dairy cattle has exacerbated the scientific community’s frustration with the U.S. Department of Agriculture after the agency again failed to include basic information needed to track how the virus is changing as it spreads. Like a large tranche of sequences that the USDA uploaded to a public database on April 21, this week’s data dump did not include information about where and when the sequenced samples wer

Labelling 363
article thumbnail

Reunion raises over $100M to build a better psychedelic drug

BioPharma Dive

The funding will help Reunion pay for a mid-stage study testing its most advanced medicine — essentially a synthetic version of the hallucinogenic psilocin — in women with postpartum depression.

120
120

More Trending

article thumbnail

Delphia starts up with $67M to make a new type of cancer drug

BioPharma Dive

Delphia is developing medicines designed to overstress certain cellular pathways to the point tumor cells die, an approach the biotech calls “activation lethality.

119
119
article thumbnail

Opinion: Why isn’t there agreement on when women need to start getting mammograms?

STAT

If, after reading the latest recommendation on breast cancer screening by the United States Preventive Services Task Force (USPSTF), you feel like your head is spinning, that’s understandable. The task force’s newest advice , which gives a “B” grade in favor of routine mammograms for women in their 40s, reverses its 2016 statement saying the test should be optional for such women.

325
325
article thumbnail

MHRA publishes strategy on AI regulation

European Pharmaceutical Review

The Medicines and Healthcare products Regulatory Agency (MHRA) has published a policy paper on its strategic approach to artificial intelligence (AI). It summarises the MHRA’s view on the UK government’s white paper on AI regulation published in 2023. Following publication of this white paper, the government requested that the MHRA outline the steps the agency is working on in relation to its expectations.

115
115
article thumbnail

Opinion: The U.S. needs a reliable supply of baby formula. A new bill in Congress can help

STAT

Families in America should never have to scrounge for baby formula. The United States needs a diverse and resilient supply of infant formula. Boosting the ability of smaller companies to compete in this market against the three large formula makers — Abbott, Mead Johnson, and Nestlé Gerber — could help make shortages a thing of the past.

321
321
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

Pace, acceleration, and precision are the name of the game

pharmaphorum

Security and privacy within biotech are critical points of consideration and discussion as the industry continues to innovate at speed, and it is such aspects that are central to today’s podcast with Zach Powers, chief information security officer at Benchling, the R&D cloud platform for the biotech industry.

118
118
article thumbnail

STAT+: Novartis extends radiopharma plans with $1 billion acquisition

STAT

Novartis already produces the leading drug in the radiopharmaceutical field. Now, it is devoting even more attention to these cancer treatments with a new acquisition.  Novartis is paying $1 billion upfront and up to an additional $750 million if certain milestones are met to acquire startup Mariana Oncology, the latter company announced Thursday.

310
310
article thumbnail

The top pharmaceutical companies by R&D expenditure

Pharmaceutical Technology

From Merck & Co to Sanofi, Pharmaceutical Technology lists the leading pharmaceutical companies spending the most on R&D in 2023.

article thumbnail

STAT+: Gilead gets a boost from California court in a case over slow-walking an HIV drug

STAT

In a boost for Gilead Sciences, the California Supreme Court agreed to review a contentious legal theory that thousands of HIV patients have used in a closely watched case to argue drugmakers can be held negligent for failing to develop a medicine. Earlier this year, a state appeals court ruled the company could be held liable for halting further development of an HIV medicine that was safer than an HIV drug it was already selling.

article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

What is the future of biologic medicines?

European Pharmaceutical Review

Recent developments in the biologic therapies sector include the authorisation of Pyzchiva ® (biosimilar ustekinumab) by the European Commission, and promising 12-month data for Roche’s subcutaneous injection of OCREVUS ® (ocrelizumab) for relapsing or primary progressive multiple sclerosis. The biologics market is expected to continue its fast growth despite the slowdown in funding observed in the past year.

article thumbnail

STAT+: Amgen goes all in on injectable obesity drug as it scraps early-stage pill

STAT

Amgen said Thursday that it will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate that’s seen as a potential competitor to Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The injectable drug, called MariTide, is in a Phase 2 trial for obesity, and Chief Executive Bob Bradway said on an earnings call that “we are very encouraged with the results” from an interim analysis of that trial.

Diabetes 298
article thumbnail

Unravelling the impact of ICH E6(R3) on Good Clinical Practice

pharmaphorum

The updated ICH E6(R3) Good Clinical Practice guidelines are here - discover what's changed and how clinical trials will need to adapt. This in-depth post unravels the key impacts of E6(R3).

110
110
article thumbnail

STAT+: Transcarent, Glen Tullman’s health tech unicorn, raises $126 million

STAT

Transcarent, the fast-moving company helmed by health tech investor and former Livongo CEO Glen Tullman, today announced $126 million in Series D funding valuing the company at $2.2 billion. The investment round was led by venture capital giant General Catalyst and 7wireVentures, where Tullman is a managing partner. Transcarent will use the funding to support development of artificial intelligence capabilities across the enterprise, growing its business, and pursuing acquisitions, Tullman told S

297
297
article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

Novartis to buy Mariana Oncology in radiopharmaceutical expansion

BioPharma Dive

The $1 billion dollar acquisition will add to Novartis’ pipeline of the targeted radiation drugs, giving it a potential lung cancer treatment.

110
110
article thumbnail

STAT+: Novo Nordisk defends Ozempic’s price in face of Senate scrutiny

STAT

Novo Nordisk defended the prices of its blockbuster diabetes and obesity drugs Ozempic and Wegovy amid a Senate probe into what the company charges. Speaking on an earnings call Thursday, CEO Lars Fruergaard Jørgensen said the company launched the treatments at similar prices to earlier generations in the drug class, despite their having greater efficacy, making them “an attractive value proposition.

Diabetes 294
article thumbnail

New patient card to be introduced for finasteride

The Pharmacist

A patient alert card warning of potential psychiatric and sexual side effects of finasteride will be introduced into packs the medicine this year, following a review into the drug’s safety. Finasteride is used by men as a 1mg dose under the brand name Propecia to treat hair loss, and as a 5mg dose under the […] The post New patient card to be introduced for finasteride appeared first on The Pharmacist.

article thumbnail

STAT+: Novartis’ $3 billion MorphoSys boondoggle

STAT

This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up  here  to get it delivered every Thursday to their inbox. Boston-area beaches are closed to dogs starting May 1, so Bo got one last chance this past weekend to dig and play in the sand. Pssst: You can sneak your dog to Wingaersheek Beach on summer nights, after the parking monitors leave at 5 p.m.

273
273
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Educating on the rewards of a career in life sciences

pharmaphorum

Pursue your passion for science with a rewarding career in life sciences. Learn how a job in biology, biotech, or health sciences offers intellectual stimulation and the chance to improve lives.

109
109
article thumbnail

STAT+: Lawmakers unlikely to permanently extend telehealth flexibilities this year

STAT

WASHINGTON — Members of Congress appear poised to advance another short-term extension of pandemic-era telehealth flexibilities instead of permanently addressing the issue, seven sources familiar with the talks said. During the Covid-19 pandemic, lawmakers allowed Medicare patients to access telehealth services in more places and for a greater variety of providers than before, but some of those flexibilities are set to expire at the end of the year.

Packaging 274
article thumbnail

Final April price concessions published by DHSC

The Pharmacist

The Department of Health and Social Care (DHSC) has published its final list of price concessions for April 2024. The final update comes after the end of month and follows concerns raised by Community Pharmacy England (CPE) over potential delays to concessions announcements adding ‘another layer of complexity’ to the process. The first April price […] The post Final April price concessions published by DHSC appeared first on The Pharmacist.

article thumbnail

STAT+: BridgeBio spins out oncology company as it focuses on heart drug

STAT

BridgeBio Pharma is spinning out its oncology subsidiary into a fully independent company, as it concentrates its resources on an anticipated launch of its pivotal heart drug. The subsidiary, a company called TheRAS that is developing treatments for cancers with mutations in the KRAS gene, will become BridgeBio Oncology Therapeutics. The spinout is backed by $200 million in private financing led by Cormorant Asset Management and Omega Funds, with participation from other firms including Deerfiel

239
239
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Bayer secures full ownership of Bayer Zydus Pharma, acquires remaining 25 per cent stakes

Express Pharma

Bayer Pharmaceuticals and Zydus Lifesciences announced the successful conclusion of their joint venture (JV) – Bayer Zydus Pharma. The 50:50 joint venture was established on January 28, 2011, for the sales and marketing of pharmaceutical products in India. Bayer is now securing full ownership of the entity, as per pre-agreed JV terms. A press statement from Bayer informed, “The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market.

Diabetes 102
article thumbnail

UnitedHealth’s Andrew Witty gets no pity in Congress

STAT

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine.  Sign up here  to receive it in your inbox on Tuesdays and Thursdays. Witty gets no pity UnitedHealth CEO Andrew Witty was the target of both a Senate and House hearing yesterday, and he faced the full wrath and exasperation of lawmakers angry about the Change Healthcare cyberattack that disrupted payment processing across the country, my

article thumbnail

Maiva Pharma raises Rs 1,000 cr from Morgan Stanley, India Life Sciences Fund

Express Pharma

Maiva Pharma has raised Rs. 1,000 crores in primary and secondary funding from a fund managed by Morgan Stanley Private Equity Asia and India Life Sciences Fund – IV (ILSF – IV), which have jointly acquired a controlling stake from existing investors and infused primary capital in the company. This is Maiva’s first private equity fundraise.

Dosage 100
article thumbnail

The biotech news you need to read this morning

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Good morning, we’re nearing the end of my second week writing this newsletter. I want to know what you think! Share your feedback in  this survey  if you haven’t already.

article thumbnail

UK health offers course for professionals to learn from the forefront of psychedelic research hub

Outsourcing Pharma

Clerkenwell Health is proud to announce the launch of its foundation course for Psychedelic-Assisted Therapy, a comprehensive 30-hour program that brings together leading experts in the field.

97